search
Back to results

Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema (STRIDE)

Primary Purpose

Diabetic Macular Edema

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
triamcinolone acetonide
triamcinolone acetonide
Sponsored by
SurModics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetic Macular Edema focused on measuring DME

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with clinically observable macular edema associated with diabetic retinopathy in study eye
  • Macular edema in study eye is associated with

    1. visual acuity of 20/40 or worse; and
    2. retinal thickening in the fovea as seen on biomicroscopic examination
    3. angiographic evidence of leakage involving the perifoveal capillary net
  • Failure of macular edema to improve with prior macular photocoagulation, or the patient is unlikely to benefit from macular photocoagulation in the opinion of the investigator
  • Patients must be 18 years of age and older
  • Patients must be willing and able to return for scheduled follow up examinations for 3 years after initial surgery.
  • Patients must sign and be given a copy of the written Informed Consent form.

Exclusion Criteria:

  • Monocular, or vision worse than 20/400 in the fellow eye
  • Visual acuity worse than 20/200 20/200 and < 34 letters read in the study eye
  • Use of depot periocular steroids in the study eye within the past 30 days
  • Current use of >15 mg/day of oral steroids
  • Known steroid responder
  • Ocular hypertension > 22 mmHg in the study eye or need for more than one medication to maintain IOP < 22 mmHg.
  • Cup to disc ratio of > 0.8 in the study eye
  • Prior filtration surgery or glaucoma implant surgery in the study eye
  • Any active ocular infection in either eye
  • History of herpetic ocular infection in the study eye
  • Macular ischemia, defined as angiographic evidence of enlargement of the foveal avascular zone to 1 disc area or larger, centered on the fovea
  • Macular or panretinal photocoagulation treatment in the study eye within the past 90 days; laser capsulotomy within the past 90 days
  • Planned or known need for ocular surgery in the study eye within 90 days after enrollment and treatment
  • Any condition that precludes the subject's ability to comply with study requirements, including examinations or the completion of the study; or any condition that precludes the examiner's ability to obtain reliable fundus photography, angiography, or OCT images
  • Females who are pregnant or lactating, and premenopausal females who are unwilling to use a medically accepted method of birth control for the duration of the study
  • Participation in another investigational trial within 30 days prior to enrollment or during the study period
  • Uncontrolled hypertension (systolic BP > 160 mm Hg and/or diastolic BP > 90 mmHg)
  • Uncontrolled diabetes (HbA1c > 13)
  • Chronic renal failure requiring dialysis or anticipated renal transplant
  • Retinal or choroidal neovascularization in the study eye; anticipated need for panretinal photocoagulation within the next 30 days
  • Macular edema in the study eye known to be due to a cause other than diabetic retinopathy
  • Use of immunosuppressant drugs

Sites / Locations

  • Retinal Consultants of Arizona
  • California Retina Consultants
  • Kresege Eye Institute
  • VitreoRetinal Surgery, PA

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Slow release formulation

fast release formulation

Arm Description

Slow release formulation, helical intravitreal triamcinolone implant

fast release formulation, helical intravitreal triamcinolone implant

Outcomes

Primary Outcome Measures

Best Corrected Visual Acuity

Secondary Outcome Measures

OCT
IOP
Slit lamp exam/funduscopy
Fluorescein angiography
Adverse events

Full Information

First Posted
June 4, 2009
Last Updated
June 7, 2023
Sponsor
SurModics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00915837
Brief Title
Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema
Acronym
STRIDE
Official Title
Phase 1 Prospective, Randomized, Double-Masked, Multicenter Study to Evaluate the Safety and Tolerability of Two Dose Levels of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema
Study Type
Interventional

2. Study Status

Record Verification Date
June 2009
Overall Recruitment Status
Completed
Study Start Date
June 2005 (undefined)
Primary Completion Date
April 2009 (Actual)
Study Completion Date
May 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
SurModics, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This Phase 1 study will evaluate the safety, tolerability and duration of effect of a helical intravitreal triamcinolone implant for the treatment of diabetic macular edema over a three-year period.
Detailed Description
The Helical Intravitreal Triamcinolone Implant is intended to provide sustained release of triamcinolone acetonide into the vitreous chamber of the eye.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Macular Edema
Keywords
DME

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Slow release formulation
Arm Type
Experimental
Arm Description
Slow release formulation, helical intravitreal triamcinolone implant
Arm Title
fast release formulation
Arm Type
Experimental
Arm Description
fast release formulation, helical intravitreal triamcinolone implant
Intervention Type
Drug
Intervention Name(s)
triamcinolone acetonide
Intervention Description
Helical intravitreal triamcinolone implant- 925 mcg drug; slow release formulation approximately 1-3 mcg/day
Intervention Type
Drug
Intervention Name(s)
triamcinolone acetonide
Intervention Description
Helical intravitreal triamcinolone implant- 925 mcg drug; fast release formulation approximately 3-5 mcg/day
Primary Outcome Measure Information:
Title
Best Corrected Visual Acuity
Time Frame
every 3 months for 36 months
Secondary Outcome Measure Information:
Title
OCT
Time Frame
every 3 months for 36 months
Title
IOP
Time Frame
every 3 months for 36 months
Title
Slit lamp exam/funduscopy
Time Frame
every 3 months for 36 months
Title
Fluorescein angiography
Time Frame
every 3 months for 36 months
Title
Adverse events
Time Frame
every 3 months for 36 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with clinically observable macular edema associated with diabetic retinopathy in study eye Macular edema in study eye is associated with visual acuity of 20/40 or worse; and retinal thickening in the fovea as seen on biomicroscopic examination angiographic evidence of leakage involving the perifoveal capillary net Failure of macular edema to improve with prior macular photocoagulation, or the patient is unlikely to benefit from macular photocoagulation in the opinion of the investigator Patients must be 18 years of age and older Patients must be willing and able to return for scheduled follow up examinations for 3 years after initial surgery. Patients must sign and be given a copy of the written Informed Consent form. Exclusion Criteria: Monocular, or vision worse than 20/400 in the fellow eye Visual acuity worse than 20/200 20/200 and < 34 letters read in the study eye Use of depot periocular steroids in the study eye within the past 30 days Current use of >15 mg/day of oral steroids Known steroid responder Ocular hypertension > 22 mmHg in the study eye or need for more than one medication to maintain IOP < 22 mmHg. Cup to disc ratio of > 0.8 in the study eye Prior filtration surgery or glaucoma implant surgery in the study eye Any active ocular infection in either eye History of herpetic ocular infection in the study eye Macular ischemia, defined as angiographic evidence of enlargement of the foveal avascular zone to 1 disc area or larger, centered on the fovea Macular or panretinal photocoagulation treatment in the study eye within the past 90 days; laser capsulotomy within the past 90 days Planned or known need for ocular surgery in the study eye within 90 days after enrollment and treatment Any condition that precludes the subject's ability to comply with study requirements, including examinations or the completion of the study; or any condition that precludes the examiner's ability to obtain reliable fundus photography, angiography, or OCT images Females who are pregnant or lactating, and premenopausal females who are unwilling to use a medically accepted method of birth control for the duration of the study Participation in another investigational trial within 30 days prior to enrollment or during the study period Uncontrolled hypertension (systolic BP > 160 mm Hg and/or diastolic BP > 90 mmHg) Uncontrolled diabetes (HbA1c > 13) Chronic renal failure requiring dialysis or anticipated renal transplant Retinal or choroidal neovascularization in the study eye; anticipated need for panretinal photocoagulation within the next 30 days Macular edema in the study eye known to be due to a cause other than diabetic retinopathy Use of immunosuppressant drugs
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Herbert L Cantrill, MD
Organizational Affiliation
VitreoRetinal Surgery, PA
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Pravin U Dugel, MD
Organizational Affiliation
Retinal Consultants of Arizona
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Tamer H Mahmoud, MD, PhD
Organizational Affiliation
Kresege Eye Institute
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Robert L Avery, MD
Organizational Affiliation
California Retinal Consultants
Official's Role
Principal Investigator
Facility Information:
Facility Name
Retinal Consultants of Arizona
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85014
Country
United States
Facility Name
California Retina Consultants
City
Santa Barbara
State/Province
California
ZIP/Postal Code
93103
Country
United States
Facility Name
Kresege Eye Institute
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Facility Name
VitreoRetinal Surgery, PA
City
Edina
State/Province
Minnesota
ZIP/Postal Code
55435
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema

We'll reach out to this number within 24 hrs